Tumor lysis syndrome associated with reduced immunosuppression in a lung transplant recipient

Mayo Clinic Proceedings

Volumn 81, Issue 10, 2006, Pages 1397-1399

  Khan, Behram A ^a   Deel, Conrad ^b   Hellman, Richard N ^a  

^a INDIANA UNIVERSITY   (United States)

^b METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMYLASE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BICARBONATE; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CISPLATIN; CORTICOSTEROID; ENOXAPARIN; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFUSION FLUID; METHOTREXATE; PACLITAXEL; POLYSTYRENESULFONATE SODIUM; PREDNISONE; RITUXIMAB; TACROLIMUS; TAMOXIFEN; TRIACYLGLYCEROL LIPASE;

ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; AGED; ANURIA; ARTICLE; B CELL LYMPHOMA; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE REDUCTION; FATALITY; FATIGUE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LETHARGY; LUNG FIBROSIS; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; OLIGURIA; POSTOPERATIVE COMPLICATION; TUMOR LYSIS SYNDROME; URIC ACID NEPHROPATHY;

EID: 33749266177     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.10.1397     Document Type: Article

References (15)

1. Kelton J, Kelley WN, Holmes EW. A rapid method for the diagnosis of acute uric acid nephropathy. Arch Intern Med. 1978;138:612-615.
2. Kjellstrand CM, Campbell DC II, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med. 1974;133:349-359.
3. Tsokos GC, Balow JE, Spiegel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore). 1981;60:218-229.
4. Veenstra J, Krediet RT, Somers R, Arisz L. Tumor lysis syndrome and acute renal failure in Burkitt's lymphoma: description of 2 cases and a review of the literature on prevention and management. Neth J Med. 1994;45: 211-216.
5. Jasek AM, Day HJ. Acute spontaneous tumor lysis syndrome. Am J Hematol. 1994;47:129-131.
6. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-554.
7. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol. 2000;27:322-334.
8. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998-3003.
9. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology. 2000;36:69-86.
10. Penn I. Cancers complicating organ transplantation [editorial]. N Engl J Med. 1990;323:1767-1769.
11. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol. 2002;118:728-740.
12. Allen U, Hebert D, Moore D, Dror Y, Wasfy S, Canadian PTLD Survey Group-1998. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience. Pediatr Transplant. 2001;5:198-203.
13. Gonzalez-Barca E, Domingo-Domenech E, Gomez-Codina J, et al. First-line treatment with rituximab improves survival of patients with post-transplant lymphoproliferative disease (PTLD) [abstract]. Blood. 2004;104: 39a. Abstract 1406.
14. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71:1076-1088.
15. Sklarin NT, Markham M. Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol. 1995;18:71-73.